EI-220
Cancer (precision immunotherapy)
PreclinicalActive
Key Facts
Indication
Cancer (precision immunotherapy)
Phase
Preclinical
Status
Active
Company
About Elixiron Immunotherapeutics
Taiwan biotech delivering precision immunotherapies for neurodegeneration, autoimmunity, and cancer via mRNA and antibody platforms.
View full company profile